ATRT-26. The PI3k inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumor...

por Findlay, Tyler, Malebranche, Kristen, Raabe, Eric, Eberhart, Charles, Rubens, Jeffrey
Publicado 2022

ATRT-16. THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS

por Malebranche, Kristen, Findlay, Tyler, Geethadevi, Anupa, Eberhart, Charles, Raabe, Eric, Rubens, Jeffrey
Publicado 2023

ATRT-09. COMBINATION OF THE PI3K INHIBITOR PAXALISIB WITH THE NUCLEOSIDE ANALOG GEMCITABINE ACTIVATES THE INTEGRATED STRESS RESPONSE AND EXTENDS SURVIVAL IN ORTHOTOPIC MODELS OF AT...

por Findlay, Tyler, Malebranche, Kristen, Geethadevi, Anupa, Eberhart, Charles, Raabe, Eric, Rubens, Jeffrey
Publicado 2023

ATRT-04. TARGETING THE COREST COMPLEX HELPS REPROGRAM AT/RT’S ABNORMAL EPIGENETIC LANDSCAPE TOWARD A DIFFERENTIATION PHENOTYPE

por Geethadevi, Anupa, Collard, Marianne, Vaidya, Nikhil, Findlay, Tyler, Malebranche, Kristen, Eberhart, Charles, Raabe, Eric, Cole, Philip, Alani, Rhoda, Rubens, Jeffrey
Publicado 2023

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

por Parkhurst, Ashlyn, Wang, Sabrina Z., Findlay, Tyler R., Malebranche, Kristen J., Odabas, Arman, Alt, Jesse, Maxwell, Micah J., Kaur, Harpreet, Peer, Cody J., Figg, William D., Warren, Katherine E., Slusher, Barbara S., Eberhart, Charles G., Raabe, Eric H., Rubens, Jeffrey A.
Publicado 2022